Search Results
Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
ECHELON-1 study of brentuximab vedotin as frontline therapy for Hodgkin's lymphoma
An updated analysis of ECHELON-1: 1L brentuximab vedotin + chemotherapy in stage III/IV classical HL
A Study of Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphoma
Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHL
ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVD
The Rationale for Exploring Brentuximab Vedotin Plus AVD in Hodgkin Lymphoma
Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHL
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
Research Builds On Positive ECHELON-1 Study in Hodgkin Lymphoma
